Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascletis Pharma, Inc. ( (HK:1672) ) has shared an update.
Ascletis Pharma Inc. has announced the successful demonstration of an ultra-long-acting subcutaneous depot maintenance formulation of its small molecule GLP-1 receptor agonist, ASC30, which showed a 75-day observed half-life in a U.S. Phase Ib study involving participants with obesity. This advancement supports once-quarterly administration, addressing a significant unmet need for maintenance therapy in chronic weight management. The formulation demonstrated favorable tolerability with minimal gastrointestinal side effects, potentially enhancing patient compliance and quality of life.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs for chronic diseases. The company specializes in small molecule drugs and has a market focus on chronic weight management therapies.
Average Trading Volume: 8,240,346
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.39B
See more insights into 1672 stock on TipRanks’ Stock Analysis page.